Peter Blume-Jensen's Net Worth
$22.4 Million
Who is Peter Blume-Jensen?
Peter Blume-Jensen has an estimated net worth of $22.4 Million. This is based on reported shares in Acrivon Therapeutics, Inc..
SEC CIK
Peter Blume-Jensen's CIK is 0001950499
Past Insider Trading and Trends
2022 was Peter Blume-Jensen's most active year for acquiring shares with 4 total transactions. Peter Blume-Jensen's most active month to acquire stocks was the month of October. 2024 was Peter Blume-Jensen's most active year for disposing of shares, totalling 4 transactions. Peter Blume-Jensen's most active month to dispose stocks was the month of April. 2023 saw Peter Blume-Jensen paying a total of $130,387.40 for 527,599 shares, this is the most they've acquired in one year. In 2023 Peter Blume-Jensen cashed out on 272,628 shares for a total of $1,214,236.84, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Acrivon Therapeutics, Inc. (ACRV) Snapshot price: $8.08
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -3.18% | -79.62K |
$9.19 | -$731,671.04 | 2.42M |
Aug 21
| |||
Form 4
| -2.33% | -59.77K |
$7.02 | -$419,550.30 | 2.5M |
Aug 14
| |||
Form 4
| -2.10% | -54.92K |
$8.36 | -$459,114.48 | 2.56M |
May 14
| |||
Form 4
| -1.57% | -41.86K |
$3.40 | -$142,327.40 | 2.62M |
Feb 14
| |||
Form 4
| -8.25% | -239.02K |
$5.08 | -$1,214,236.84 | 2.66M |
Nov 14
| |||
Form 4
| +20.55% | 493.99K |
—
|
—
| 2.9M |
Aug 21
| |||
Form 4
| +1.42% | 33.6K |
$3.88 | $130,387.40 | 2.4M |
May 31
| |||
Form 4
| +130.80% | 1.52M |
—
|
—
| 2.69M |
Nov 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |